INVEX Therapeutics Ltd (IXC)

Snapshot

IXC's Principal Activity is the reformulation of Exenatide to optimise the delivery of the drug for patients with IIH, completing regulatory submissions and feedback from global regulatory bodies including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on a Phase III clinical trial in IIH, and the prosecution of the Group's patent portfolio.

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Dr Megan Baldwin	Non-Executive Director	Feb 2021	Dr Megan Baldwin Non-Executive Director Dr Baldwin is an experienced biotechnology executive, having over 20 years' experience working on therapeutic drug development programs for cancer and ophthalmic indications. Dr Baldwin is CEO and Managing Director of Opthea Limited (ASX: OPT; NASDAQ: OPT). Under Dr Baldwin's leadership, Opthea has advanced its ophthalmology program through Phase I and Phase II clinical development. It was added to the S&P/ASX 300 in June 2020 and in October 2020 completed initial public offering (IPO) and listing on the US NASDAQ exchange to progress two pivotal Phase III studies in wet AMD. Prior to Opthea, Dr Baldwin was employed at Genentech (now Roche) as a postdoctoral researcher before moving to Genentech's commercial division. Dr Baldwin also serves on the Board of Ausbiotech.
Dr Thomas (Tom) Duthy	Executive Director	Oct 2020	Dr Thomas (Tom) Duthy Executive Director Dr Duthy has over 15 years of financial markets experience having worked in sell-side equity research, and senior executive roles across investor relations and corporate development. Dr Duthy is the Founder and CEO of Nemean Group Pty Ltd. Prior to establishing Nemean in October 2018, Dr Duthy was the Global Head of Investor Relations & Corporate Development at Sirtex Medical Limited (ASX:SRX). Prior to Sirtex, Tom spent ten years as a leading sell-side Healthcare & Biotechnology analyst at Taylor Collison Limited, focused mainly on small cap companies.
Dr Alexandra J Sinclair	Chief Scientific Officer,Executive Director	Jun 2019	Dr Alexandra J Sinclair Chief Scientific Officer,Executive Director Dr Sinclair is a Clinician Scientist and Neurology Consultant in the Metabolic Neurology Group at the Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, The University of Birmingham, UK. She runs the Headache service and Idiopathic Intracranial Hypertension Service at University Hospital Foundation Trust. Professor Sinclair is on the MRC Neuroscience and Mental Health Board and the Midland Neuroscience Teaching and Research Fund Board, as well as being Chair of the Brain Research UK Scientific Advisory Board. Previously, she was an elected board member of the IHS and was the Deputy Chair for the Association for British Neurologists grouping for Headache and Pain (ABN AAG). She was on the research committee for the Association for British Neurologists and was also the previous patron of the patient charity IIH UK.
Mrs Narelle Warren	Chief Financial Officer,Company Secretary	Mar 2019	Mrs Narelle Warren Chief Financial Officer,Company Secretary Ms Warren has over twenty years of corporate advisory, financial management and company secretarial experience. Ms Warren has coordinated and assisted in corporate transactions, including acquisitions, divestments and raising funds via private and public equity markets.
Mr David McAuliffe	Non-Executive Director	Mar 2019	Mr David McAuliffe Non-Executive Director Mr McAuliffe is an experienced company director and entrepreneur who has had over twenty years' experience, in the international biotechnology field. During that time, he was involved in capital raisings and in-licensing of technologies. He is a founder of several companies in Australia, France and the United Kingdom, many of which have become public companies. Mr McAuliffe is the President of the Dyslexia - Speld Foundation WA (Inc).
Dr Jason Loveridge	Non-Executive Chairman,Non-Executive Director	Mar 2019	Dr Jason Loveridge Non-Executive Chairman,Non-Executive Director Dr Loveridge is a founder of Invex and also CEO of 4SC AG, a German publicly listed oncology company. He has more than thirty years of international experience across Europe, Asia and the US in senior management positions in life sciences companies and as an investment professional dealing in both privately held and publicly traded companies. Additionally, he has transactional experience in the sale and partnering of biotechnology assets.

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
08/04/21	Megan Baldwin	Issued	400,000	$0.775	$310,000	Issue of options
18/11/20	Thomas (Tom) Duthy	Issued	800,000	$0.805	$644,000	Issue of options
22/11/19	Alexandra Sinclair	Issued	800,000	$0.71	$568,000	Issue of options
22/11/19	David McAuliffe	Issued	200,000	$0.71	$142,000	Issue of options
22/11/19	Jason Loveridge	Issued	800,000	$0.71	$568,000	Issue of options
22/11/19	Narelle Warren	Issued	400,000	$0.71	$284,000	Issue of options

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Alexandra Sinclair	27/08/2021	2,500,000	N/A	800,000	N/A
Thomas (Tom) Duthy	27/08/2021	N/A	106,923	800,000	N/A
Megan Baldwin	27/08/2021	N/A	N/A	400,000	N/A
Jason Loveridge	27/08/2021	3,374,246	N/A	800,000	N/A
Narelle Warren	27/08/2021	N/A	200,000	400,000	N/A
David McAuliffe	27/08/2021	N/A	3,350,001	200,000	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
Tattarang	8,846,154	11.77%
Tisia Nominees Pty Ltd <Henderson Family A/C>	4,000,000	5.32%
Anthony Grist	3,597,700	4.79%
Dr Jason Loveridge	3,374,462	4.49%
Mr David Jerimiah Mcauliffe	3,350,001	4.46%
Jk Nominees Pty Ltd <The Jk A/C>	3,000,000	3.99%
Alexandra Jean Sinclair	2,500,000	3.33%
Mrs Kathryn Salkilld	2,293,000	3.05%
The University Of Birmingham	2,000,000	2.66%
Bannaby Investments Pty Limited <Bannaby Super Fund A/C>	1,625,000	2.16%
Sunset Capital Management Pty Ltd <Sunset Superfund A/C>	1,518,175	2.02%
BNP Paribas Nominees Pty Ltd HUB24 Custodial Serv Ltd <DRP A/C>	1,390,000	1.85%
Cityscape Asset Pty Ltd <Cityscape Family A/C>	1,250,000	1.66%
Citicorp Nominees Pty Limited	1,184,837	1.58%
Sandhurst Trustees Ltd <Collins St Value Fund A/C>	1,081,924	1.44%
J P Morgan Nominees Australia Pty Limited	655,050	0.87%
Peter Kyros Pty Ltd <Kyros Sf A/C>	583,616	0.78%
Palla Nominees Pty Ltd <P C Blackman S/F No 2 A/C>	580,000	0.77%
HSBC Custody Nominees (Australia) Limited	561,504	0.75%
Magaurite Pty Ltd <Peter Nelson Super Fund A/C>	560,000	0.75%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$1.30	30 June

IXC Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.